Spago Nanomedical AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 13
- Market Cap
- -
Clinical Trials
4
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Phase 1
Recruiting
- Conditions
- Solid TumorMetastatic CancerLocally Advanced Solid TumorUnresectable Solid TumorRecurrent Solid TumorRefractory Cancer
- Interventions
- First Posted Date
- 2023-12-28
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Spago Nanomedical AB
- Target Recruit Count
- 90
- Registration Number
- NCT06184035
- Locations
- 🇦🇺
Cancer Research South Adelaide, Adelaide, South Australia, Australia
🇦🇺St Vincent Hospital Melbourne, Melbourne, Victoria, Australia
Efficacy of SN132D in Patients With Suspected Endometriosis
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Spago Nanomedical AB
- Target Recruit Count
- 8
- Registration Number
- NCT05664828
- Locations
- 🇸🇪
Kvinnokliniken, Skåne University Hospital, Malmö, Skåne, Sweden
A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Spago Nanomedical AB
- Target Recruit Count
- 14
- Registration Number
- NCT04080024
- Locations
- 🇸🇪
Gothia Forum Clinical Trial Center, Gothenburg, Sweden
🇸🇪CTC Clinical Trial Consultants AB, Uppsala, Sweden
News
No news found